1xa5: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1xa5.gif|left|200px]]
{{Seed}}
[[Image:1xa5.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1xa5|  PDB=1xa5  |  SCENE=  }}  
{{STRUCTURE_1xa5|  PDB=1xa5  |  SCENE=  }}  


'''Structure of Calmodulin in complex with KAR-2, a bis-indol alkaloid'''
===Structure of Calmodulin in complex with KAR-2, a bis-indol alkaloid===




==Overview==
<!--  
3'-(beta-Chloroethyl)-2',4'-dioxo-3,5'-spiro-oxazolidino-4-deacetoxyvinbla stine (KAR-2) is a potent anti-microtubular agent that arrests mitosis in cancer cells without significant toxic side effects. In this study we demonstrate that in addition to targeting microtubules, KAR-2 also binds calmodulin, thereby countering the antagonistic effects of trifluoperazine. To determine the basis of both properties of KAR-2, the three-dimensional structure of its complex with Ca(2+)-calmodulin has been characterized both in solution using NMR and when crystallized using x-ray diffraction. Heterocorrelation ((1)H-(15)N heteronuclear single quantum coherence) spectra of (15)N-labeled calmodulin indicate a global conformation change (closure) of the protein upon its binding to KAR-2. The crystal structure at 2.12-A resolution reveals a more complete picture; KAR-2 binds to a novel structure created by amino acid residues of both the N- and C-terminal domains of calmodulin. Although first detected by x-ray diffraction of the crystallized ternary complex, this conformational change is consistent with its solution structure as characterized by NMR spectroscopy. It is noteworthy that a similar tertiary complex forms when calmodulin binds KAR-2 as when it binds trifluoperazine, even though the two ligands contact (for the most part) different amino acid residues. These observations explain the specificity of KAR-2 as an anti-microtubular agent; the drug interacts with a novel drug binding domain on calmodulin. Consequently, KAR-2 does not prevent calmodulin from binding most of its physiological targets.
The line below this paragraph, {{ABSTRACT_PUBMED_15596444}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15596444 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15596444}}


==About this Structure==
==About this Structure==
Line 31: Line 35:
[[Category: Kar-2]]
[[Category: Kar-2]]
[[Category: Vinca alkaloid]]
[[Category: Vinca alkaloid]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 14:46:08 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 00:09:09 2008''